GYRE Stock Overview
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gyre Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.29 |
| 52 Week High | US$30.40 |
| 52 Week Low | US$8.26 |
| Beta | 0 |
| 11 Month Change | -18.78% |
| 3 Month Change | -12.07% |
| 1 Year Change | -41.83% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 67.76% |
Recent News & Updates
Shareholder Returns
| GYRE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.9% | 2.4% | 2.2% |
| 1Y | -41.8% | 16.2% | 31.7% |
Return vs Industry: GYRE underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: GYRE underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| GYRE volatility | |
|---|---|
| GYRE Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GYRE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GYRE's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 593 | Han Ying | www.gyretx.com |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.
Gyre Therapeutics, Inc. Fundamentals Summary
| GYRE fundamental statistics | |
|---|---|
| Market cap | US$1.01b |
| Earnings (TTM) | -US$88.82m |
| Revenue (TTM) | US$105.03m |
9.2x
P/S Ratio-10.9x
P/E RatioIs GYRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GYRE income statement (TTM) | |
|---|---|
| Revenue | US$105.03m |
| Cost of Revenue | US$3.96m |
| Gross Profit | US$101.08m |
| Other Expenses | US$189.90m |
| Earnings | -US$88.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.03 |
| Gross Margin | 96.23% |
| Net Profit Margin | -84.57% |
| Debt/Equity Ratio | 0% |
How did GYRE perform over the long term?
See historical performance and comparison